ABIVAX obtains regulatory and ethics clearance in Spain to begin second Phase IIa clinical trial for ABX464 in HIV/AIDS patients

Study tassess long-lasting effect of ABX464 on viral load reduction following conclusion of treatment in patients controlled by Darunavir/Ritonavir

Initial results expected in Q4 2016 

Paris (France), April 19th 2016 - ABIVAX (Euronext Paris: FR0012333284 – ABVX), an emerging leader in developing and commercializing antiviral therapies and therapeutic vaccines for infectious diseases like HIV/AIDS and chronic hepatitis B (CHB), today announced that its second Phase IIa study with ABX464, a first-in-class drug candidate for the treatment of patients with HIV/AIDS, has been approved by Regulatory and Ethics Committees in Spain.  Additional approvals in Belgium and France are expected in the near future.

 

 

Press contacts

Caroline Carmagnol 

abivax@alizerp.com

+ 33 6 64 18 99 59 or
+ 33 1 44 54 36 65

 Standard: +33 1 53 83 08 41